PGEN · Precigen, Inc.
$5.42
+2.03% last session
End-of-day data · updated 2026-07-29
Market cap
$2B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-25.1
Dividend yield
—
Beta
1.00
Avg volume
5M
Employees
0K
2D change
2.03%
5D change
—
10D change
11.72%
30D change
-6.59%
60D change
27.42%
MTD change
5.33%
YTD change
32.30%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — PGEN
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-05-28
Latest call per bank · past 12 months
JP Morgan
Neutral$0.00
-100.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-05-28 | HC Wainwright & Co. | Maintains | Buy | $11.00 → $14.00 |
| 2026-05-14 | Citizens | Maintains | Market Outperform | $9.00 → $11.00 |
| 2026-05-14 | HC Wainwright & Co. | Maintains | Buy | $10.00 → $11.00 |
| 2026-03-26 | Citizens | Maintains | Market Outperform | $8.00 → $9.00 |
| 2026-03-26 | HC Wainwright & Co. | Maintains | Buy | $9.00 → $10.00 |
| 2025-11-14 | HC Wainwright & Co. | Maintains | Buy | $8.50 → $9.00 |
| 2025-08-19 | JMP Securities | Maintains | Market Outperform | $6.00 → $8.00 |
| 2025-08-19 | HC Wainwright & Co. | Reiterates | Buy | $8.50 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 58 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 14.7% above the 50-day MA ($4.82).
- Price vs 200-day MA: Trading 30.7% above the 200-day MA ($4.23).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.01) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($1.57) and high ($5.92).
PGEN Price Chart
Loading chart for PGEN…
Fundamentals
About Precigen, Inc.
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$124B 8.2% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$73B -9.7% YTD
ARGX
argenx SE
$55B 3.7% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$39B -27.5% YTD
RVMD
Revolution Medicines, Inc.
$39B 130.8% YTD
RPRX
Royalty Pharma plc
$35B 56.7% YTD
ONC
BeOne Medicines Ltd.
$34B 8.8% YTD
INCY
Incyte Corporation
$26B 31.6% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.